

Regarding TOP 3 (Discharge of the Supervisory Board members from their responsibilities for financial year 2017):

SUPERVISORY BOARD UNTIL MAY 24, 2017

NAME	FUNCTION
Prof. Dr. Horst Domdey	Chairman of the Supervisory Board
Antoinette Hiebeler-Hasner	Deputy Chairwoman of the Supervisory Board
Dr. Yita Lee	Member of the Supervisory Board

SUPERVISORY BOARD FROM MAY 24, 2017

NAME	FUNCTION
Prof. Dr. Horst Domdey	Chairman of the Supervisory Board Member of the Supervisory Board since 2013
Antoinette Hiebeler-Hasner	Deputy Chairwoman of the Supervisory Board Member of the Supervisory Board since 2016
Dr. Yita Lee	Member of the Supervisory Board Member of the Supervisory Board since 2013
Dr. Keith Manchester	Member of the Supervisory Board Member of the Supervisory Board since 2017
Dr. Gerd Zettlmeissl	Member of the Supervisory Board Member of the Supervisory Board since 2017
Ronald Scott	Member of the Supervisory Board Member of the Supervisory Board since 2017

PRESENCE AT ORDINARY SUPERVISORY BOARD MEETINGS

MEMBER	21.03.2017	24.05.2017	25.07.2017	28.09.2017	29.11.2017
Prof. Dr. Horst Domdey	+	+	+	+	+
Antoinette Hiebeler-Hasner	+	+	+	+	+
Dr. Yita Lee	+	+	+	+	+
Dr. Keith Manchester (since 24.05.2017)	n.a.	+	+	+	+
Ronald Scott (since 24.05.2017)	n.a.	+	+	+	+
Dr. Gerd Zettlmeissl (since 24.05.2017)	n.a.	+	+	+	+

+ = present; - = not present; n.a. = not applicable

SUPERVISORY BOARD COMMITTEES

COMMITTEE	UNTIL 24.05.2017	24.05.2017 UNTIL 28.11.2017	SINCE 28.11.2017
Nomination and Compensation Committee	Dr. Yita Lee Chairman	Dr. Keith Manchester Chairman	Dr. Gerd Zettlmeissl Chairman
	Prof. Dr. Horst Domdey	Prof. Dr. Horst Domdey	Prof. Dr. Horst Domdey
	Antoinette Hiebeler-Hasner	Dr. Yita Lee	Dr. Yita Lee
Audit Committee	Antoinette Hiebeler-Hasner Chairwoman	Antoinette Hiebeler-Hasner Chairwoman	Antoinette Hiebeler-Hasner Chairwoman
	Prof. Dr. Horst Domdey	Ronald Scott	Ronald Scott
	Dr. Yita Lee	Dr. Gerd Zettlmeissl	Dr. Keith Manchester

PRESENCE AT MEETINGS OF THE AUDIT COMMITTEE

MEMBER	16.03.2017	09.05.2017	02.08.2017	08.11.2017
Antoinette Hiebeler-Hasner	+	+	+	+
Prof. Dr. Horst Domdey	+	+	n.a.	n.a.
Dr. Yita Lee	+	+	n.a.	n.a.
Ronald Scott	n.a.	n.a.	+	+
Dr. Gerd Zettlmeissl	n.a.	n.a.	+	+

+ = present; - = not present; n.a. = not applicable

PRESENCE AT MEETINGS OF THE NOMINATION AND COMPENSATION COMMITTEE

MEMBER	21.03.2017	26.07.2017	28.09.2017	28.11.2017
Antoinette Hiebeler-Hasner	+	n.a.	n.a.	n.a.
Prof. Dr. Horst Domdey	+	+	+	+
Dr. Yita Lee	+	+	+	+
Dr. Keith Manchester	n.a.	+	+	n.a.
Dr. Gerd Zettlmeissl	n.a.	n.a.	n.a.	+

+ = present; - = not present; n.a. = not applicable

CVs of the Supervisory Board

Prof. Dr. Horst Domdey, Chairman of the Supervisory Board

Born: 1951

Horst Domdey, a trained biochemist, held research positions in Germany, Switzerland and the United States, before he became Professor for Biochemistry at the University of Munich in 1994. In the same year he co-founded Medigene, one of the first biotech companies in Germany. In 1996 he successfully led the Munich Biotech Initiative into the German BioRegio Competition. Since 1997 he has been the Managing Director of BioM, the cluster development and management organization of the Munich Biotech Cluster. Since 2006 he also manages the Bavarian Biotechnology Cluster. Since 2003, he is the scientific director of the Bavarian Genome Network BayGene, and since 2011 the coordinator of the Bavarian Center for Molecular Biosystems BioSysNet. He has been cofounder of BIO Deutschland, of the Association of the German BioRegions and of the Council of the European BioRegions (CEBR). In 2010 the Munich Biotech Cluster became – under his leadership – one of the winners in the German Leading Edge Cluster Competition.

Essential positions:

- Managing Director of BioM Biotech Cluster Management GmbH, Planegg, Germany
- Liquidator of BioM AG Munich Biotech Development i.L., Planegg, Germany

Antoinette Hiebeler-Hasner

Born: 1958

Antoinette Hiebeler-Hasner has started her career with Peat Marwick Mitchell & Co. now KPMG after having studied business administration at the Ludwigs-Maximilians University in Munich. As a tax consultant she founded her own tax consultancy firm in 1988. After various mergers with other consultancies the optegra consultancy group was established, with offices in Cologne and in Munich. With more than 140 employees optegra provides services such as legal and tax consulting, as well as auditing. Since October 2017, this company has been operating as Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft after the integration of the optegra Group into the globally active Vistra Group. Furthermore, Mrs. Hiebeler-Hasner

and her brothers founded the H3 Aerospace GmbH & Co.KG, which purchased the Grob Aircraft AG in 2009. Grob Aircraft SE is a medium-sized company, with more than 250 employees, which develops and produces training aircrafts that are successfully sold world-wide. Apart from the professional abilities of Mrs. Hiebeler-Hasner, which include proficiency with regard to financial statements, securing of accounting continuity and tax consultancy, Mrs. Hiebeler-Hasner is also able to offer a huge entrepreneurial expertise due to her various business activities.

Essential positions:

- Chairperson of the Supervisory Board of Grob Aircraft SE
- Member of the Supervisory Board of Ventuz Technology AG
- Partner of Vistra GmbH & Co. KG Wirtschaftsprüfungsgesellschaft
- Managing Director of Wilder Kaiser GmbH Steuerberatungsgesellschaft (Tax Consultants)

Dr. Yita Lee

Born: 1971

Yita Lee currently serves as Chief Scientific Officer of Sinphar Group, a publicly listed company in Taiwan, where he oversees the progress of the company's R&D projects. As the President of Sinphar's Subsidiary CanCap Pharmaceutical Ltd., he is in charge of plant manufacturing of pharmaceutical and nutraceutical soft-gelatin products in British Columbia, Canada. Furthermore, he holds positions as Director of SynCore New Drug co., Ltd., and as Director of ZuniMed Biotech Co., Ltd., since 2008 and 2012, respectively. Yita Lee earned his Ph.D. degree at Michael Smith Laboratories & Department of Chemical and Biological Engineering, University of British Columbia. In 2008, he was appointed as director of the Taiwan Bio Industry Organization, as well as director of the Mont Jade Science and Technology Association (Canada) in 2006.

Essential positions:

- Member of the Board of Directors of Sinphar Pharmaceutical Co., Ltd., Yilan, Taiwan
- Member of the Board of Directors of SynCore Biotechnology Co., Ltd., Yilan, Taiwan
- Member of the Board of Directors of ZuniMed Biotech Co., Ltd., Yilan, Taiwan

- Member of the Board of Directors of CanCap Pharmaceutical Ltd., Richmond, Canada

Dr. Keith Manchester

Year of birth: 1968

Keith Manchester serves as a Managing Director and the Head of Life Sciences at QVT Financial LP, New York, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life sciences companies. Dr. Manchester also serves as a director of Arbutus Biopharma Corporation, Myovant Sciences Ltd. and Roivant Sciences, Inc. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, Inc., a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman, Sachs & Co. Dr. Manchester received his A.B. degree from Harvard College and his M.D. degree from Harvard Medical School.

Essential positions:

Publicly listed companies:

- Arbutus Biopharma Corporation, Canada: Director since 2015
- Myovant Sciences Ltd., Bermuda: Director since 2016

Other companies/organizations:

- Dr. Manchester is Managing Director and Head at Life Sciences QVT Financial LP
- Roivant Sciences, Inc., Delaware, USA: Director since 2014, and Roivant Sciences Ltd., Bermuda: Director since 2014

Ronald Scott

Year of birth: 1955

Ronald Scott has served Basilea Pharmaceutical International Ltd., Basel, Switzerland, as Chief Executive Officer since January 2013. He was Basilea's Chief Operating Officer from January through December 2012, and served as Basilea's Chief Financial Officer from the Company's founding in 2000 through January 2012 as well as ad interim Chief Financial Officer from February 2013 until November 2013. From 2004 to October 2011, Mr. Scott served on the Board of Directors and was a co-founding Board member in 2000. Prior to joining Basilea, Mr. Scott worked at Roche Holding AG (Roche) in management positions in Pharmaceutical Finance, Licensing, and the Roche Corporate Finance Mergers and Acquisitions group. Prior to joining Roche, Mr. Scott worked for Prudential Investment Corporation in the United States as Director in Prudential's Finance and International Business Development Units, managing divestitures and joint venture transactions. Mr. Scott has a bachelor's degree from Utah State University (USA) and a master's degree from Harvard University (USA).

Essential positions:

- Chief Executive Officer at Basilea Pharmaceutical International Ltd.

Dr. Gerd Zettlmeissl

Year of birth: 1955

Gerd Zettlmeissl has more than 25 years of scientific and leadership experience in the biopharmaceutical industry. He currently serves as representative of the Board of Directors of several non-profit organizations and biotech companies. Until early 2015 he was chairman of GlycoVaxyn (Switzerland), an innovative vaccine company acquired by GlaxoSmithKline. He is the former CEO of the Austrian-based biotechnology company Intercell AG (now Valneva SE). While at Intercell AG from 2001 to 2011, he built the company from a private start-up venture to a publicly listed international organization with more than 400 employees. As CEO, he secured global regulatory approval for and led the launch of an improved Japanese Encephalitis vaccine, and oversaw efforts to build and advance a broad based development portfolio of vaccines. Prior to joining Intercell, Dr. Zettlmeissl was Managing Director of Chiron Behring GmbH and held senior management roles in biopharmaceutical R&D and Technical Operations at Chiron Corp. and Behringwerke AG. In 2010, he was named Vaccine Biotech CEO of the Year at the World Vaccine Congress. Dr. Zettlmeissl holds a doctoral degree in biochemistry of the University of Regensburg and did a post- doctoral fellowship at the Institut Pasteur Paris in virology.

Essential positions:

Publicly listed companies:

- ASIT biotech, Brussels, Belgium: Member of the Supervisory Board since 2011; Chairman since March 2017

Other companies/organizations:

- MSD Wellcome Trust Hilleman Laboratories, New Delhi, India: Chairman of the Supervisory Board since 2013
- Themis Bioscience GmbH, Vienna, Austria: Chairman of the Supervisory Board since 2015
- Aeras, Rockville, MD, USA: Member of the Supervisory Board since 2011